Funding for this research was provided by:
National Center for Advancing Translational Sciences (ULI TR003107)
Received: 23 November 2021
Accepted: 28 April 2022
First Online: 23 May 2022
: This protocol was submitted to the University of Arkansas for Medical Sciences Institutional Review Board and was determined to not be human subject research.
: No individual person’s data are presented in this manuscript.
: Dr. Bradley Martin received royalties from Trestle Tree LLC, for the commercialization of an opioid risk prediction tool. Dr. Bradley Martin also receives consulting revenue from eMaxHealth LLC for studies unrelated to this manuscript. All other authors associated with this manuscript have no conflicts of interest to declare at this time.